Natus Medical Incorporated (BABY) Shares Bought by Mirador Capital Partners LP
Mirador Capital Partners LP boosted its position in shares of Natus Medical Incorporated (NASDAQ:BABY) by 57.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,552 shares of the medical equipment provider’s stock after buying an additional 17,618 shares during the period. Mirador Capital Partners LP owned about 0.15% of Natus Medical worth $1,694,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in BABY. Ameritas Investment Partners Inc. purchased a new stake in shares of Natus Medical during the first quarter worth about $110,000. Sei Investments Co. raised its stake in shares of Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after buying an additional 728 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Natus Medical by 94.0% in the first quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 1,543 shares during the last quarter. State of Alaska Department of Revenue raised its stake in shares of Natus Medical by 1.7% in the first quarter. State of Alaska Department of Revenue now owns 3,630 shares of the medical equipment provider’s stock worth $142,000 after buying an additional 60 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Natus Medical during the second quarter worth about $204,000. 92.65% of the stock is currently owned by institutional investors.
Natus Medical Incorporated (NASDAQ BABY) traded down 0.46% during trading on Monday, hitting $32.30. 24,335 shares of the company’s stock traded hands. Natus Medical Incorporated has a 12-month low of $31.65 and a 12-month high of $44.39. The stock has a market cap of $1.05 billion, a P/E ratio of 55.98 and a beta of 0.93. The firm’s 50-day moving average price is $35.42 and its 200 day moving average price is $36.37.
Natus Medical (NASDAQ:BABY) last posted its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.33 by $0.01. Natus Medical had a net margin of 4.20% and a return on equity of 12.09%. The business had revenue of $122.20 million for the quarter, compared to analyst estimates of $121.99 million. During the same quarter in the prior year, the firm earned $0.39 EPS. The firm’s quarterly revenue was up 27.3% compared to the same quarter last year. Analysts anticipate that Natus Medical Incorporated will post $1.70 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Natus Medical Incorporated (BABY) Shares Bought by Mirador Capital Partners LP” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/28/natus-medical-incorporated-baby-shares-bought-by-mirador-capital-partners-lp.html.
A number of analysts have issued reports on the company. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Benchmark Co. restated a “buy” rating and issued a $48.00 price target (down previously from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Finally, Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the stock. Natus Medical currently has an average rating of “Hold” and an average target price of $45.00.
In other news, insider James B. Hawkins bought 4,000 shares of the stock in a transaction dated Thursday, June 15th. The shares were acquired at an average price of $33.98 per share, with a total value of $135,920.00. Following the acquisition, the insider now owns 578,023 shares in the company, valued at $19,641,221.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director William M. Moore sold 3,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $34.10, for a total transaction of $102,300.00. Following the completion of the sale, the director now directly owns 30,410 shares in the company, valued at approximately $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.